Tulisokibart for lung diseases, interstitial

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Mar 2022: Trial registered, NCT05270668
  2. 29 Mar 2022: Trial started, NCT05270668

The trials

NCT05270668: Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

State
Under way
Phase
Phase 2
People
154 taking part
Started
29 Mar 2022
Primary completion
16 Apr 2026
Arms
Tulisokibart
Results
None posted
  1. 8 Mar 2022: Trial registered
  2. 29 Mar 2022: Trial started

How the status changed

  1. 16 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.